Michel Sadelain has excelled in his career for more than two decades by pouring his passion for cell engineering and immunology into every project in which he has participated. Currently, he is the founding director of Memorial Sloan Kettering Cancer Center’s Center for Cell Engineering and the head of the hospital’s Gene Transfer and Gene Expression Laboratory. Additionally, Dr. Sadelain serves as a professor of medicine and immunology for the hospital’s medical school. Through these roles, he has contributed to the field of medicine in numerous ways, including his exploration of the use of genetic engineering to cure diseases. Dr. Sadelain was among the first wave of physicians to explore this technique and is now best known for the design of chimeric antigen receptors, better known as “CAR therapy.” He is also known for his expertise in gene transfer and genetic therapies, congenial and acquired disorders of the hematopoietic and immune systems, and immunotherapy.
Incredibly passionate about his field, Dr. Sadelain has authored and co-authored numerous articles and publications related to his area of study, including “Therapeutic T Cell Engineering,” “Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective,” and “Tales of Antigen Evasion from CAR Therapy.” To further exercise his passion, Dr. Sadelain formerly served as the president of the American Society of Gene Cell Therapy in 2015.
Dr. Sadelain has been consistently recognized for his many achievements in the medical field. He was the recipient of the Sultan Bin Khalifa International Award in 2013 and the Cancer Research Institute’s Award for CAR Therapy in 2012. This year, Marquis Who’s Who recognized Dr. Sadelain for his success and prominence in the field of cell engineering, medicine and immunology.
Contact Michel Sadelain:
